🇺🇸 Fosamprenavir/ritonavir in United States

52 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Thrombocytopenia — 7 reports (13.46%)
  2. Hypersplenism — 6 reports (11.54%)
  3. Intervertebral Disc Protrusion — 6 reports (11.54%)
  4. Nodular Regenerative Hyperplasia — 6 reports (11.54%)
  5. Portal Hypertension — 6 reports (11.54%)
  6. Portal Vein Thrombosis — 6 reports (11.54%)
  7. Varices Oesophageal — 6 reports (11.54%)
  8. Drug Interaction — 3 reports (5.77%)
  9. Hepatotoxicity — 3 reports (5.77%)
  10. Therapy Non-Responder — 3 reports (5.77%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Fosamprenavir/ritonavir approved in United States?

Fosamprenavir/ritonavir does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Fosamprenavir/ritonavir in United States?

ViiV Healthcare is the originator. The local marketing authorisation holder may differ — check the official source linked above.